Literature DB >> 7539508

Occurrence of antibodies reactive with more than one variant of the putative envelope glycoprotein (gp70) hypervariable region 1 in viremic hepatitis C virus-infected patients.

E Scarselli1, A Cerino, G Esposito, E Silini, M U Mondelli, C Traboni.   

Abstract

The hepatitis C virus (HCV) is a frequent cause of chronic liver disease. A mechanism proposed as being responsible for virus persistence is evasion of the host immune response through a high mutation rate in crucial regions of the viral genome. We have sequenced the hypervariable region 1 (HVR1) of the virus isolated from three serum samples, collected during 18 months of follow-up, from an asymptomatic HCV-infected patient. A synthetic peptide of 27 amino acids, corresponding to the HVR1 sequence found to be predominant in both the second and third samples, was used as the antigen for detection of antibodies by enzyme-linked immunosorbent assay (ELISA). We observed reactivity against this HVR1 sequence in the first serum sample before the appearance of the viral isolate in the bloodstream; the reactivity increased in the second and third samples while the cognate viral sequence became predominant. Moreover, our results show that antibodies from all three samples recognize a region mapping at the carboxyl-terminal part of the HVR1 and are cross-reactive with the HVR1 sequence previously found in the same patient. The presence of anti-HVR1 antibodies was investigated in a further 142 HCV patients: 121 viremic and 21 nonviremic. Two synthetic peptides were used, the first corresponding to the sequence derived from the patient described above and the second one synthesized according to the sequence of the HCV BK strain. A high frequency of positive reactions against both HVR1 variants was detected in the samples from the viremic individuals. Finally, antibodies cross-reactive with both variants were shown to be present by competitive ELISA in 6 of 10 viremic patients. The potential negative implications of this observation for the host are discussed.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7539508      PMCID: PMC189182     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  42 in total

1.  Marked sequence diversity in the putative envelope proteins of hepatitis C viruses.

Authors:  N Kato; Y Ootsuyama; T Tanaka; M Nakagawa; T Nakazawa; K Muraiso; S Ohkoshi; M Hijikata; K Shimotohno
Journal:  Virus Res       Date:  1992-02       Impact factor: 3.303

2.  Characterization of the hepatitis C virus E2/NS1 gene product expressed in mammalian cells.

Authors:  R R Spaete; D Alexander; M E Rugroden; Q L Choo; K Berger; K Crawford; C Kuo; S Leng; C Lee; R Ralston
Journal:  Virology       Date:  1992-06       Impact factor: 3.616

Review 3.  Neutralization of HIV-1: a paradox of humoral proportions.

Authors:  P L Nara; R R Garrity; J Goudsmit
Journal:  FASEB J       Date:  1991-07       Impact factor: 5.191

4.  Hypervariable regions in the putative glycoprotein of hepatitis C virus.

Authors:  M Hijikata; N Kato; Y Ootsuyama; M Nakagawa; S Ohkoshi; K Shimotohno
Journal:  Biochem Biophys Res Commun       Date:  1991-02-28       Impact factor: 3.575

5.  Expression of the amino-terminal half of the NS1 region of the hepatitis C virus genome and detection of an antibody to the expressed protein in patients with liver diseases.

Authors:  Y Inoue; R Suzuki; Y Matsuura; S Harada; J Chiba; Y Watanabe; I Saito; T Miyamura
Journal:  J Gen Virol       Date:  1992-08       Impact factor: 3.891

6.  Lack of protective immunity against reinfection with hepatitis C virus.

Authors:  P Farci; H J Alter; S Govindarajan; D C Wong; R Engle; R R Lesniewski; I K Mushahwar; S M Desai; R H Miller; N Ogata
Journal:  Science       Date:  1992-10-02       Impact factor: 47.728

7.  Sequence evolution of the hypervariable region in the putative envelope region E2/NS1 of hepatitis C virus is correlated with specific humoral immune responses.

Authors:  L J van Doorn; I Capriles; G Maertens; R DeLeys; K Murray; T Kos; H Schellekens; W Quint
Journal:  J Virol       Date:  1995-02       Impact factor: 5.103

8.  Evidence for immune selection of hepatitis C virus (HCV) putative envelope glycoprotein variants: potential role in chronic HCV infections.

Authors:  A J Weiner; H M Geysen; C Christopherson; J E Hall; T J Mason; G Saracco; F Bonino; K Crawford; C D Marion; K A Crawford
Journal:  Proc Natl Acad Sci U S A       Date:  1992-04-15       Impact factor: 11.205

9.  Expression of MBP-HCV NS1/E2 fusion protein in E. coli and detection of anti-NS1/E2 antibody in type C chronic liver disease.

Authors:  E Mita; N Hayashi; K Ueda; A Kasahara; H Fusamoto; A Takamizawa; K Matsubara; H Okayama; T Kamada
Journal:  Biochem Biophys Res Commun       Date:  1992-03-31       Impact factor: 3.575

10.  Typing hepatitis C virus by polymerase chain reaction with type-specific primers: application to clinical surveys and tracing infectious sources.

Authors:  H Okamoto; Y Sugiyama; S Okada; K Kurai; Y Akahane; Y Sugai; T Tanaka; K Sato; F Tsuda; Y Miyakawa
Journal:  J Gen Virol       Date:  1992-03       Impact factor: 3.891

View more
  25 in total

Review 1.  Immunopathogenesis of viral hepatitis.

Authors:  M U Mondelli
Journal:  Clin Rev Allergy Immunol       Date:  2000-04       Impact factor: 8.667

2.  Long-term evolution of the hypervariable region of hepatitis C virus in a common-source-infected cohort.

Authors:  J McAllister; C Casino; F Davidson; J Power; E Lawlor; P L Yap; P Simmonds; D B Smith
Journal:  J Virol       Date:  1998-06       Impact factor: 5.103

Review 3.  The quasispecies of hepatitis C virus and the host immune response.

Authors:  P Farci; J Bukh; R H Purcell
Journal:  Springer Semin Immunopathol       Date:  1997

4.  Vaccination with dendritic cells pulsed with hepatitis C pseudo particles induces specific immune responses in mice.

Authors:  Kilian Weigand; Franziska Voigt; Jens Encke; Birgit Hoyler; Wolfgang Stremmel; Christoph Eisenbach
Journal:  World J Gastroenterol       Date:  2012-02-28       Impact factor: 5.742

5.  Enhancement of immunoglobulin G2a and cytotoxic T-lymphocyte responses by a booster immunization with recombinant hepatitis C virus E2 protein in E2 DNA-primed mice.

Authors:  M K Song; S W Lee; Y S Suh; K J Lee; Y C Sung
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

6.  Evolutionary rate and genetic drift of hepatitis C virus are not correlated with the host immune response: studies of infected donor-recipient clusters.

Authors:  J P Allain; Y Dong; A M Vandamme; V Moulton; M Salemi
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

7.  Antigenicity and immunogenicity of novel chimeric hepatitis B surface antigen particles with exposed hepatitis C virus epitopes.

Authors:  H J Netter; T B Macnaughton; W P Woo; R Tindle; E J Gowans
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

8.  Antigenic cooperation among intrahost HCV variants organized into a complex network of cross-immunoreactivity.

Authors:  Pavel Skums; Leonid Bunimovich; Yury Khudyakov
Journal:  Proc Natl Acad Sci U S A       Date:  2015-05-04       Impact factor: 11.205

Review 9.  Variability or conservation of hepatitis C virus hypervariable region 1? Implications for immune responses.

Authors:  Mario U Mondelli; Antonella Cerino; Annalisa Meola; Alfredo Nicosia
Journal:  J Biosci       Date:  2003-04       Impact factor: 1.826

10.  Identification of a domain containing B-cell epitopes in hepatitis C virus E2 glycoprotein by using mouse monoclonal antibodies.

Authors:  J W Lee; K m Kim; S H Jung; K J Lee; E C Choi; Y C Sung; C Y Kang
Journal:  J Virol       Date:  1999-01       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.